PLURI is a world-leading expert in biotechnological clinical grade (GMP) manufacturing for the PLX-PAD cell product characterized by a variety of immunomodulatory properties.
Since 2003, Pluri-Biotech has been taking single placenta cells, growing them into billions of cells, and creating groundbreaking cell-based therapies to treat patients around the world. Due to their nature, these placental cells have no need for genetic matching – a huge advantage in cell therapy.
Pluri-Biotech’s  preclinical and clinical programs explore a wide range of therapeutic areas, including vascular disease, inflammation-related conditions, muscle injuries and hematological disorders.
Our growing pipeline of differentiated products includes potential candidates to meet some of medicine’s most challenging unmet needs around the world.
These are being developed in our in-house, Good Manufacturing Practices manufacturing facility.